Literature DB >> 72790

Failure of basic protein therapy for multiple sclerosis.

R E Gonsette, P Delmotte, L Demonty.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 72790     DOI： 10.1007/BF00312812

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  14 in total

1.  Intensive immunosuppression in patients with disseminated sclerosis. I. Clinical response.

Authors:  E M Lance; M Kremer; J Abbosh; V E Jones; S Knight; P B Medawar
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

2.  Intensive immunosuppression in the treatment of multiple sclerosis.

Authors:  J Ring; J Seifert; G Lob; K Coulin; H Angstwurm; E Frick; B Brass; J Mertin; H Backmund; W Brendel
Journal:  Lancet       Date:  1974-11-09       Impact factor: 79.321

3.  Myelin basic protein administration in multiple sclerosis.

Authors:  B Campbell; P J Vogel; E Fisher; R Lorenz
Journal:  Arch Neurol       Date:  1973-07

4.  Prevention of experimental allergic encephalomyelitis by nonencephalitogenic basic peptides.

Authors:  G A Hashim; F J Schilling
Journal:  Arch Biochem Biophys       Date:  1973-05       Impact factor: 4.013

5.  Antigen-induced inhibition of experimental allergic encephalomyelitis. II. Studies in guinea pigs with the small rat myelin basic protein.

Authors:  R H Swanborg
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

6.  Effect of 'maximum immune suppression' with thoracic duct drainage, ALG, azathioprine and cortisone in some neurological disorders.

Authors:  W Brendel; J Seifert; G Lob
Journal:  Proc R Soc Med       Date:  1972-06

7.  Cyclophosphamide inhibition of experimental allergic encephalomyelitis and cellular transfer of the disease in Lewis rats.

Authors:  P Y Paterson; M A Hanson
Journal:  J Immunol       Date:  1969-12       Impact factor: 5.422

8.  Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species.

Authors:  G E Deibler; R E Martenson; M W Kies
Journal:  Prep Biochem       Date:  1972

9.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

10.  Biochemical findings in multiple sclerosis. V. Transformation of lymphocytes from patients with multiple sclerosis by human basic protein.

Authors:  F Gosseye-Lissoir; P Delmotte; H Carton
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849
View more
  12 in total

1.  Instant effect of soluble antigen on effector T cells in peripheral immune organs during immunotherapy of autoimmune encephalomyelitis.

Authors:  Francesca Odoardi; Naoto Kawakami; Zhaoxia Li; Chiara Cordiglieri; Kristina Streyl; Mikhail Nosov; Wolfgang E F Klinkert; Joachim W Ellwart; Jan Bauer; Hans Lassmann; Hartmut Wekerle; Alexander Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

2.  Treatment of experimental allergic encephalomyelitis with myelin basic protein: which route is best?

Authors:  S Levine; R Sowinski
Journal:  Neurochem Res       Date:  1984-10       Impact factor: 3.996

3.  Suppression and reversal of allergic encephalomyelitis in rhesus monkeys with basic protein and peptides.

Authors:  E H Eylar; J J Jackson; P J Kniskern
Journal:  Neurochem Res       Date:  1979-04       Impact factor: 3.996

Review 4.  Multiple sclerosis. Current concepts in management.

Authors:  B Giesser
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

Review 5.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

6.  Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease.

Authors:  F Odoardi; N Kawakami; W E F Klinkert; H Wekerle; A Flügel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-13       Impact factor: 11.205

7.  Chronic relapsing experimental allergic encephalomyelitis: CNS plaque development in unsuppressed and suppressed animals.

Authors:  C S Raine; U Traugott; S H Stone
Journal:  Acta Neuropathol       Date:  1978-08-07       Impact factor: 17.088

Review 8.  Myelin basic protein and multiple sclerosis.

Authors:  J N Whitaker
Journal:  Ital J Neurol Sci       Date:  1983-06

9.  Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

Authors:  R E Gonsette; L Demonty; P Delmotte
Journal:  J Neurol       Date:  1977-02-17       Impact factor: 4.849

10.  'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides.

Authors:  Nathali Kaushansky; Nicole Kerlero de Rosbo; Rina Zilkha-Falb; Reut Yosef-Hemo; Lydia Cohen; Avraham Ben-Nun
Journal:  PLoS One       Date:  2011-11-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.